PMID- 34121576
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 38
IP  - 1
DP  - 2021
TI  - The guiding value of microvascular invasion for treating early recurrent small 
      hepatocellular carcinoma.
PG  - 931-938
LID - 10.1080/02656736.2021.1937715 [doi]
AB  - INTRODUCTION: Hepatocellular carcinoma (HCC) patients with microvascular invasion 
      (MVI) have worse survival. Whether the presence of MVI indicates the necessity of 
      more aggressive locoregional treatments for recurrences remains to be elucidated. 
      METHODS: We reviewed patients who underwent curative hepatectomy for primary HCC 
      in our institution, and 379 patients with recurrent HCC up to three nodules 
      smaller than 3 cm were enrolled. The Kaplan-Meier method was adopted to compare 
      the secondary recurrence-free survival (sRFS) and post-recurrence survival (PRS) 
      among patients undergoing hepatectomy, RFA and transarterial chemoembolization 
      plus RFA (TACE-RFA). Cox regression analyses were performed to identify 
      independent prognostic factors. RESULTS: Both the sRFS and PRS of the MVI (-) 
      group were significantly longer than those of the MVI (+) group (p = 0.001 and 
      0.011). For patients with MVI (-), no significant difference was found in sRFS or 
      PRS among recurrent HCC patients receiving hepatectomy, RFA or TACE-RFA 
      (p = 0.149 and 0.821). A similar trend was found in patients with MVI (+) 
      (p = 0.851 and 0.960). Further analysis found that TACE-RFA provided better sRFS 
      than hepatectomy or RFA alone in patients with MVI (+) and early recurrence 
      within two years (p = 0.036 and 0.044). CONCLUSION: For HCC patients with MVI (+) 
      and early small recurrence, TACE-RFA could achieve better prognosis than 
      hepatectomy or RFA alone, while RFA alone provided comparable survival benefits 
      compared with hepatectomy or TACE-RFA in other HCC patients with small 
      recurrence.
FAU - Sun, Xuqi
AU  - Sun X
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 
      China.
AD  - Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
FAU - Yang, Ziliang
AU  - Yang Z
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 
      China.
FAU - Mei, Jie
AU  - Mei J
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 
      China.
FAU - Lyu, Ning
AU  - Lyu N
AUID- ORCID: 0000-0002-8254-1040
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Minimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen 
      University Cancer Center, Guangzhou, China.
FAU - Lai, Jinfa
AU  - Lai J
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Minimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen 
      University Cancer Center, Guangzhou, China.
FAU - Chen, Minshan
AU  - Chen M
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 
      China.
FAU - Zhao, Ming
AU  - Zhao M
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
AD  - Minimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen 
      University Cancer Center, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
SB  - IM
MH  - *Carcinoma, Hepatocellular/surgery
MH  - *Chemoembolization, Therapeutic
MH  - Humans
MH  - *Liver Neoplasms/surgery
MH  - Neoplasm Recurrence, Local/surgery
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - microvascular invasion
OT  - recurrent
OT  - survival
OT  - treatment
EDAT- 2021/06/15 06:00
MHDA- 2021/07/06 06:00
CRDT- 2021/06/14 09:15
PHST- 2021/06/14 09:15 [entrez]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1080/02656736.2021.1937715 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2021;38(1):931-938. doi: 10.1080/02656736.2021.1937715.